2Hayashi M, Tsutamodo T, Wada A. Immedinistration of mineralocorticoid receptor antagonist sporonolactone prevents postinfarct left ventricular remodeling associated with suppression of a Marker of Myocardial Collagen Synthesis in patients with first anterior acute myocardial infarction[J]. Circulation, 2003, 107:2559-2565.
4Pitt B, gannad F, Remme Wj, et al. The effec*s of spironnlactone on morbidity and mortality in patients with serve heart failure Randomized Aldoctone Evaluation Study Investigator [J]. N Engl J Med, 1999,341 (10):709 -717.
5McMurray J, Kober L, Robeeson M. et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction[J]. J Am Coll Cardiol, 2005,45 (4) : 525- 530.
7Zannad F,Alla F, Dousset B, et al. Limitation of excessive matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure[J]. Circulation, 2000, 102 :2700 -2706.
9Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation,and treatment of high blood pressure [J]. Hypertension, 2003,42(3) : 1206 -1252.
10Corry DB,Tuck ML. The effect of aldosterone on glucose me tabolism[J]. Curr Hypertens Rep,2003,5(2): 106 -109.
2Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol,2002,161 : 1773-1781.
3Matsumoto R, Yoshiyama M, Omura T, et al. Effects of aldosterone receptor antagonist and angiotensin Ⅱ type Ⅰ receptor blocker on cardiac transcrip- tional factors and mRNA expression in rats with myecardial infarction. Circ J, 2004,68 : 376-782.
4Baggiolini M. Chemokines and leukocyte traffic. Nature, 1998,392: 565-568.
5Kuwahara F, Kai H, Tokuda K, et al. Targeted deletion of CC ehemokine re- ceptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol, 2004,165:439-447.
6Siwik DA, Chang DL, Colucci WS. Interleukin-lbeta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res,2000,86:1259-1265.
7[1]Mantero F,Lucarelli G.Aldoterone antagonists in hypertension and heart failure[J].Ann Endocrinol,2000,61(1):53-60.
8[2]Toddi S,Virdis A,Mattei P,et al.Vasodilation to acetylcholioe in primayary and secondary forms of humanhypertension[J].Hypertension,1993,21(6 Pt 2):929-933.
9[3]Modena MG,Aveta P,Menozzi A,et al.Aldosterone inhibition limits collagen synthesis and progressive left ventricularen largement after anterior myocardial infraction[J].Am Heart J,2001,141:41-45.
10[4]Barr CS,Lang CC,Hanson J.Effect of adding pironolactone to in ACE inhibitor in chronic congestive heart failure secondary to coronary artery disease[J].Am J Cardial,1995,120:893-901.
4PITY B, ZANNAD F, REMME W L, et al. For the Randomi- zed aldactone evaluation study investigators. The effect of spironolactone on mortality and morbidity in patients with severe heart failure [ J ]. N Engl J Med, 1999,341 (10) : 709- 717.
5ZANNAD F, MCMURRAY J J, KRUM H, et al. Eplerenone in patients with systolic heart failure and mild symptoms [ J ]. N Engl l Med,2011,364(1) :11-21.
6MCMURRAY J J, ADAMOPOULOS S, ANKER S D, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 [ J ]. Eur Heart J, 2012,33 ( 14 ) : 1787-1847.
7YANCY C W, JESSUP M, BOZKURT B, et al. 2013 ACCF/ AHA guideline for the management of heart failure [ J ]. Circulation,2013,128 ( 16 ) : 1810-1852.
